原发性手术与原发性药物治疗晚期青光眼的成本效果比较
本研究基于治疗晚期青光眼研究(Treatment of Advanced Glaucoma Study)的随机对照试验数据,从英国国家卫生服务体系(NHS)视角进行为期2年的成本效用分析,比较新诊断晚期开角型青光眼(OAG)患者原发性手术与药物治疗的成本效果。结果显示,小梁切除术成本更高且效果更好,EQ-5D-5L的增量成本每QALY为45,456英镑;结论认为在2年时间范围内药物治疗更具成本效果。
要点
- 小梁切除术成本更高且效果更好,EQ-5D-5L增量成本每QALY为45,456英镑。
- HUI3、GUI及纳入患者成本的结果不改变研究结论,2年时间范围内药物治疗更具成本效果。
核心结论
- 在2年时间范围内,药物治疗是管理青光眼更具成本效果的方法。
- 未来研究可关注更长时间范围内治疗的成本与收益。
研究设计与样本
- 基于治疗晚期青光眼研究(随机对照试验)的试验内经济评价,比较原发性手术与药物治疗新诊断晚期OAG患者的效果。
- 从英国国家卫生服务体系(NHS)视角进行为期2年的成本效用分析,纳入患者成本。
- 主要结局为通过EQ-5D-5L、健康效用指数3(HUI3)和青光眼效用指数(GUI)测量的患者健康相关生活质量。
- 结果表示为每获得一个QALY的增量成本。
主要发现
- 小梁切除术与更高成本和更大效果相关,EQ-5D-5L结果的增量成本每QALY为45,456英镑。
- HUI3、GUI及纳入患者成本的结果不改变研究结论。
关键数值与推荐
- EQ-5D-5L的增量成本每QALY为45,456英镑。
- 手术在30,000英镑/QALY阈值下具有成本效果的可能性为12%。
- 手术在50,000英镑/QALY阈值下具有成本效果的可能性为56%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 纵向结局是未来研究的重要主题。
- 未来研究可关注更长时间范围内治疗的成本与收益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
SYNOPSIS: Advanced glaucoma is associated with sight loss. This within-trial economic evaluation compares medical and surgical management strategies. At 2 years, medication appears more cost-effective though longitudinal outcomes are an important subject in future research. BACKGROUND/AIMS: Open angle glaucoma (OAG) is a progressive optic neuropathy. Approximately 25% of newly diagnosed patients with OAG present with advanced disease in at least one eye. The vision loss associated with OAG can lead to significant impacts on vision, quality of life and health care resources. The Treatment of Advanced Glaucoma Study is a randomised controlled trial comparing the effectiveness of primary surgical and medical management for newly diagnosed advanced patients with OAG. An economic evaluation was carried out to understand the costs and benefits of each strategy. METHODS: A cost utility analysis was carried out from a National Health Service perspective over a 2-year time horizon inclusive of patient costs. The primary outcome was patient health-related quality of life measured by the EQ-5D-5L, Health Utilities Index 3 (HUI3) and Glaucoma Utility Index (GUI). Results were expressed as incremental cost per QALY gained. RESULTS: Trabeculectomy was associated with higher costs and greater effect, the EQ-5D-5L results have an incremental cost per QALY of £45,456. The likelihood of surgery being cost-effective at a £20, 000, £30,000 and £50,000 QALY threshold is 0%, 12% and 56%, respectively. The results for the HUI3, GUI and inclusion of patient costs do not change the conclusions of the study. CONCLUSION: This is the first study to evaluate management strategies for those presenting with advanced glaucoma. At a 2-year time horizon, medication is the more cost-effective approach for managing glaucoma. Future research can focus on the costs and benefits of the treatments over a longer time horizon.
引用
- Kernohan A, Homer T, Shabaninejad H, et al. Cost-effectiveness of primary surgical versus primary medical management in the treatment of patients presenting with advanced glaucoma. Br J Ophthalmol. 2022. PMID: 35882513. doi:10.1136/bjo-2021-320887
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。